Life Sciences Tools and Services
Company Overview of Cancer Research Technology Limited
Cancer Research Technology Limited operates as a cancer-focused drug discovery, technology transfer, and commercialization company. It develops and licenses oncology related opportunities with pharmaceutical and biotechnology companies; and translates academic discoveries into industrial propositions. The company engages in sourcing and developing cancer discoveries; providing technology transfer services to cancer researchers; and identifying scientific and business solutions to unmet needs in cancer. Its drug discovery programs include the identification of small molecule inhibitors against various target classes, including kinases, kinesins, methyltransferases, and molecular chaperone tar...
407 St John Street
London, EC1V 4AD
Founded in 1982
Key Executives for Cancer Research Technology Limited
Chief Executive Officer and Director
Chief Operating Officer and Chief Executive of Cancer Research UK
Head of Medicinal Chemistry
Head of Molecular Pharmacology, Biochemistry & High Throughput Screening
Head of Clinical Partnerships
Compensation as of Fiscal Year 2015.
Cancer Research Technology Limited Key Developments
EpiStem Holdings Plc Announces the Signing of a Licensing Agreement with Cancer Research Technologies and Newcastle University
Apr 20 15
Epistem Holdings Plc announced the signing of a licensing agreement with Cancer Research Technologies (CRT) and Newcastle University for access to and development of patient derived Acute Lymphoblastic Leukemia (ALL) Primagraft samples for commercial use. This agreement builds upon Epistems expertise with cell line based disseminated models of leukemia, and will further enhance the Company's ability to support pre-clinical therapeutic evaluation in haematological disease. The licensed Primagraft models include a range of fully cytogenetically characterized samples, with complete clinical history. In addition to FACs based methodologies, several of these systemic Primagraft models have been stably lentivirally transduced with a luciferase vector allowing monitoring of in-life treatment responses and evaluation of disease severity using Epistems Bruker In Vivo Xtreme Optical imaging system.
Medivir AB and Cancer Research Technology Collaborate to Develop New Class of Cancer Drugs
Apr 13 15
Medivir AB and Cancer Research Technology jointly announced a partnership to develop a new class of drugs that has shown promise for treating a range of different cancers, including pancreatic cancer. As part of the collaboration, CRT and Medivir will conduct a two-year research programme to optimize and develop small molecules targeting the cell surface protein ADAM8, which has been linked to tumour survival, cell invasion and metastasis. Under the terms of the agreement Medivir receives an exclusive, global license to research, develop, manufacture and commercialize ADAM8 inhibitor drugs resulting from development. CRT receives an upfront payment and future milestones as well as royalties on sales which are shared with the academic collaborators. Blocking ADAM8 in mice with pancreatic cancer prevented the spread of the disease, shrunk tumours and significantly extended lifespan. This is thought to be due to its involvement in cell adhesion, cell migration, inflammation and the growth of blood vessels – key processes that many cancers rely on for growth and development. High levels of the protein have been linked with more aggressive tumours including those in pancreatic, breast, brain, prostate, lung, head and neck, and kidney cancers. This research will be led by Professor Jörg Bartsch as head of the TransMIT-Project Division for Research in Neuro-Oncology at TransMIT GmbH, located at Marburg University in Germany, in collaboration with Medivir. Prof. Bartsch previously worked at King’s College London where the initial patent application was filed by King’s College IP and Licensing team. Further proof of concept studies were funded by Cancer Research UK at King’s College.
BioInvent International and Cancer Research Technology Ltd Sign Two-Year Research Collaboration with University of Southampton
Apr 9 15
BioInvent International and Cancer Research Technology Ltd. (CRT) have signed two-year research collaboration with the University of Southampton. The program aims to develop new immunotherapy treatments for cancer based on preclinical work by the Southampton group showing the potential to treat cancer using antibodies targeting OX40 and 4-1BB - known 'co-receptors' that help stimulate the production of killer T-cells during an immune response. One of the ways that tumour cells avoid detection is by suppressing immune responses to stop functional tumour specific T-cells from being produced. The team aims to develop antibodies that can reverse this process to stimulate the immune system to fight the cancer. Terms of the collaboration were not disclosed, however, BioInvent has the option to take out a license to commercialize any promising results, with the parties receiving milestone payments and a share of potential revenues. The first phase of the project aims to identify and then validate the effectiveness of the best class of antibodies to target OX40 and 4-1BB. This work will be carried out in Lund, Sweden, and Southampton, UK, using highly specialised assays and expertise developed through a prior long-standing collaboration between BioInvent and the University of Southampton.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|